In recent years, a great deal of experience with vasodilator treatment in chronic heart failure has accumulated.'-3 A number of currently available drugs have been shown to improve supine, resting haemodynamic measurements.'-'9 Yet these haemodynamic changes have not always predicted the subsequent clinical response to treatment.'5-"7 20 21 Since most heart failure patients experience symptoms predominantly with activity, several groups have begun to examine the haemodynamic effects of vasodilators during exercise."-'7 Indeed, at least one commonly used agent, prazosin, appears to have a greater effect during exercise than at rest. 28 Hydralazine and isosorbide dinitrate have fre- York Heart Association class 3 or 4) chronic congestive heart failure. All were on stable doses of digoxin and diuretics, which were continued throughout the study. The aetiology of myocardial decompensation was ischaemic heart disease in eight patients, primary cardiomyopathy in four, and hypertensive heart disease in the last. The patients' mean age was 59, with a range of 41 to 72.
STUDY DESIGN
The patients were admitted to hospital at least two days before the study in order to ensure dietary and drug compliance. On the day before catheterisation, each subject was instructed in the use of an inertial bicycle ergometer. After a period of practice, the patients exercised upright to a symptom-limited maximum, beginning at a 200 kpm/min work load and increasing by 100 kpm/min every three mrinutes. During the subsequent haemodynamic studies, measurements were performed in the final two minutes at the highest work load completed during the preliminary test. During subsequent tests, if the patients were able, exercise was then continued until a symptom-limited maximum to permit measurement of maximal oxygen consumption.
The following day, a balloon-tipped thermodilution catheter was placed in a pulmonary artery and a radial artery was cannulated. After several hours during which haemodynamic stability was established, supine resting and upright exercise measurements of heart rate, systolic, diastolic, mean arterial pressure, pulmonary artery pressure, right atrial pressure, pulmonary capillary wedge pressure, and cardiac output were performed. In both positions, the transducer was placed at a level 5 cm vertical distance below the sternal angle. The electrocardiogram, systemic arterial, and pulmonary artery pressures were recorded continuously during exercise. Right atrial, pulmonary capillary wedge, and mean pressures were recorded at one minute intervals. Arterial and pulmonary artery blood gases were drawn at peak exercise for calculation of oxygen consumption (see below).
Isosorbide dinitrate was then begun with an initial 5 mg sublingual dose. Subsequently, the dosage was increased until the supine pulmonary capillary wedge pressure was consistently lowered below 15 The letters above the bars indicate that particular drug regimen produced a significant change (at least p < 005) from the control measurements (C) or those on isosorbide dinitrate (I) or hydralazine (H) alone. Note that isosorbide dinitrate and combined treatment lowered both pulmonary capillary wedge (PCW) and right atrial (RA)
pressures, while hydralazine and combined treatment raised cardiac output (CO) and stroke volume index (SVI).
given alone and in combination on the resting haemodynamic measurements are shown in Fig. 1 and Table 1 Fig. 4 . At rest, isosorbide dinitrate produced predominantly a shift to the left, while during exercise the change was clearly upward as well as to the left. Hydralazine had only a small effect on pulmonary capillary wedge pressure at rest and thus produced predominantly an upward shift, whereas during exercise the change was clearly leftward and upward. Combined treatment in both situations produced additive benefit, but this was particularly impressive during exercise. During exercise, the improvement in most indices was significantly greater with hydralazine plus isosorbide dinitrate than with either agent alone.
ACUTE EFFECTS OF VASODILATOR TREATMENT ON EXERCISE CAPACITY
In addition to the haemodynamic measurements at the predetermined near maximal level of exercise, cardiac output and arteriovenous oxygen difference were determined at peak exercise, allowing the calculation of maximal oxygen consumption. These findings are illustrated in Fig. 3 16 29 This may reflect indirect effects of these agents, such as a reduction in mitral regurgitation or an increase in renal blood flow. Another likely explanation for this discrepancy is that heart failure patients may differ in their haemodynamic responses to exercise,'2 and that these agents may have different haemodynamic effects during exercise than at rest. 28 Since most patients experience symptoms primarily with activity, the need to examine the effect of drugs during exercise as well as at rest has been in- group.bmj.com on January 28, 2018 -Published by http://heart.bmj.com/ Downloaded from performance may occur rapidly in some patients but develop over a period of time in others.
IMPLICATIONS
These findings show the importance of examining exercise as well as resting haemodynamic measurements in evaluating drug treatment for heart failure. Since both isosorbide dinitrate and hydralazine each lower wedge pressure and raise cardiac output -during exercise, they may be efficacious individually in treating some patients. Combined treatment produces striking improvement during exercise and at rest, and thus our findings further support the use of this vasodilator regimen. 
